V001-BCMA

N/A

Report date: 2026/01/19 20:02:34

Base Information

Drug NameV001-BCMA
Drug Alias NameV001-BCMA
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsImmunoglobulin G4-Related DiseaseScleroderma, SystemicLupus Erythematosus, Systemic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTongji Hospital
China Registration ClassN/A

Develop Information

Active CompaniesTongji Hospital
Inactive CompaniesN/A
Active IndicationsImmunoglobulin G4-Related DiseaseScleroderma, SystemicLupus Erythematosus, Systemic +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A